<DOC>
	<DOCNO>NCT02454088</DOCNO>
	<brief_summary>This single-center , investigator-initiated , double-blinded , randomize , bilateral-comparison pilot study injectable Calcium hydroxylapatite without Triamcinolone acetate treatment volume loss dorsum area hand .</brief_summary>
	<brief_title>A Single-Center Investigator-Initiated Evaluator-Bilateral-Comparison Pilot Study Injectable Calcium Hydroxylapatite With Without Triamcinolone Acetate Treatment Volume Loss Dorsum Areas Hands</brief_title>
	<detailed_description />
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>1 . Cutaneous soft tissue atrophy dorsum hand , indicate Merz Validated Hand Grading Scale score 2 , 3 4 . 2 . Males females good general health 22 year age old . 3 . Must willing give sign inform consent form photographic release form . 4 . Subject plan revolumizing rejuvenation treatment dorsum area hand . 5 . For female subject childbearing potential , must willing use acceptable form birth control entire course study . All systemic birth control measure must consistent use least 30 day prior study enrollment participation . A female consider childbearing potential unless postmenopausal , without uterus and/or ovary , bilateral tubal ligation . Acceptable method birth control : oral contraceptive , contraceptive patches/rings/implants , Implanon® , DepoProvera® , doublebarrier method ( e.g . condom spermicide ) , abstinence and/or vasectomy partner document second acceptable method birth control , subject become sexually active . 6 . Negative urine pregnancy test result time study entry ( applicable ) . 7 . Must willing comply study dose complete entire course study . 1 . A subject uncontrolled systemic disease . A potential subject therapy systemic disease yet stabilize consider entry study . 2 . A Subject currently use systemic steroid . 3 . A subject significant history current evidence medical , psychological disorder , investigator 's opinion , would preclude enrollment study . 4 . A subject history presence skin condition/disease might interfere diagnosis evaluation study parameter ( i.e. , atopic dermatitis , eczema , psoriasis ) . 5 . A subject active bacterial , fungal , viral infection treatment area . 6 . A subject active systemic fungal infection . 7 . A subject prior history allergy product medication use study . 8 . A subject planning cosmetic procedure study area study period , treatment perform investigator . 9 . A subject history previous fat transfer injectable polyllactic acid study area within past five year . 10 . A subject previous history calcium hydroxylapatite treatment area within past year . 11 . A subject previous history ablative laser surgery treatment area within past year . 12 . A female subject pregnant , nurse infant planning pregnancy study . 13 . Subjects know autoimmune disease compromise immune system i.e . HIV , AIDS current chemotherapy . 14 . Subjects know bleed disorder receive medication likely increase risk bleed result injection per investigator discretion . 15 . Subjects history hypertrophic scarring . 16 . Subjects cancerous precancerous lesion , unhealed wound treatment area . 17 . Current participation participation within 30 day prior start study drug investigational research study .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Volume</keyword>
	<keyword>Hands</keyword>
	<keyword>Filler</keyword>
	<keyword>Radiesse</keyword>
	<keyword>Calcium hydroxylapatite</keyword>
</DOC>